CESAR Study in Prostate Cancer With Temsirolimus Added to Standard Docetaxel Therapy (CEPTAS)

NCT01206036 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

19

Enrollment

OTHER

Sponsor class

Conditions

Prostatic Neoplasms

Interventions

DRUG: Docetaxel
DRUG: Temsirolimus

Sponsor

Central European Society for Anticancer Drug Research